Allarity Therapeutics, Inc. (ALLR) Income Statement
ALLR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsALLR revenue and net income
Where ALLR's revenue goes
2025Each bar shows an amount and its share of revenue. ALLR kept −3,509.7% of revenue as net income.
ALLR profit margins
ALLR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | −1.2% |
| Gross profit | — | — | — | −1.2% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ALLR quarterly EPS vs estimates
Allarity Therapeutics beat the analyst EPS estimate in 6 of the last 7 quarters. Next report: November 13, 2026 (estimate $-0.21).
ALLR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $320,000 | $0 | $0 | $0 | $0 | $0 | $120,000 | $1.5M | $1.5M | $143,277 |
| Cost of revenue | $0 | $9,000 | $37,000 | $120,000 | $106,000 | $86,000 | $0 | $5.1M | $2.2M | $0 |
| Gross profit | $320,000 | −$9,000 | −$37,000 | −$120,000 | −$106,000 | −$86,000 | $120,000 | −$3.6M | −$761,495 | $143,277 |
| Research & development | $6.6M | $6.1M | $7.1M | $6.9M | $14.2M | $4.2M | $6.4M | — | — | — |
| Sales, general & admin | $6.3M | $11.4M | $10.0M | $10.0M | $12.4M | $4.1M | $3.9M | — | — | — |
| Total operating expenses | $12.9M | $27.2M | $17.1M | $34.5M | $26.6M | $8.3M | $17.7M | $1.4M | $3.1M | $4.6M |
| Operating income | −$12.6M | −$27.2M | −$17.1M | −$34.5M | −$26.6M | −$8.3M | −$17.6M | −$5.0M | −$3.8M | −$4.5M |
| Interest income | $801,000 | $533,000 | $30,000 | $30,000 | $0 | $0 | $7,000 | — | — | — |
| Interest expense | $185,000 | $653,000 | $498,000 | $223,000 | $640,000 | $320,000 | $3.3M | $233,236 | $2,417 | $43,697 |
| Income before taxes | −$11.2M | −$24.9M | −$11.8M | −$17.6M | −$26.5M | −$6.4M | −$19.0M | −$3.5M | −$5.0M | −$4.4M |
| Income taxes | — | −$381,000 | $83,000 | −$1.5M | $133,000 | $198,000 | −$4.6M | −$1.1M | −$95,086 | −$766,892 |
| Net income | −$11.2M | −$24.5M | −$11.9M | −$16.1M | −$26.6M | −$6.6M | −$14.3M | −$2.3M | −$4.9M | −$3.7M |
| EBITDA | −$11.0M | −$24.2M | −$11.3M | −$17.3M | −$25.8M | −$6.0M | −$15.6M | −$4.9M | −$3.8M | −$4.2M |
| EPS (diluted) | −$0.80 | −$670.97 | −$123432.56 | −$593318.61 | −$1000000.19 | −$0.04 | −$0.28 | −$0.05 | −$0.14 | −$0.46 |
| Gross margin | 100.0% | — | — | — | — | — | 100.0% | −247.9% | −52.2% | 100.0% |
| Operating margin | −3,939.1% | — | — | — | — | — | −14,675.8% | −341.2% | −263.4% | −3,132.1% |
| Net margin | −3,509.7% | — | — | — | — | — | −11,927.5% | −157.0% | −335.7% | −2,570.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $25,000 | $320,000 | $0 | $0 | $0 | $6,000 | $0 | $0 | $112,000 | $112,000 | $0 |
| Cost of revenue | — | −$26,000 | $0 | — | $12,000 | $11,000 | $1,000 | $5,000 | $1,000 | $2,000 | $9,000 | $18,000 |
| Gross profit | — | $51,000 | $320,000 | — | −$12,000 | −$11,000 | −$1,000 | −$5,000 | −$1,000 | −$2,000 | $103,000 | −$18,000 |
| Research & development | $1.3M | $1.3M | $1.7M | $1.2M | $2.3M | $1.4M | $1.8M | $1.0M | $1.1M | $2.2M | $2.6M | $1.9M |
| Sales, general & admin | $1.3M | $1.4M | $1.6M | $1.3M | $1.8M | $1.6M | $5.5M | $1.6M | $2.3M | $2.1M | $2.3M | $2.5M |
| Total operating expenses | $2.7M | $2.7M | $3.2M | $2.5M | $4.1M | $3.0M | $7.3M | $12.3M | $3.4M | $4.2M | $4.9M | $4.4M |
| Operating income | −$2.7M | −$2.7M | −$2.9M | −$2.5M | −$4.1M | −$3.0M | −$7.3M | −$12.3M | −$3.4M | −$4.2M | −$4.9M | −$4.4M |
| Interest income | $217,000 | $163,000 | $155,000 | $187,000 | $237,000 | $222,000 | $219,000 | $261,000 | $53,000 | $0 | $3,000 | $12,000 |
| Interest expense | $719,000 | $229,000 | $59,000 | $57,000 | $12,000 | $57,000 | $75,000 | $50,000 | $426,000 | $102,000 | $230,000 | $34,000 |
| Income before taxes | −$3.4M | −$2.8M | −$3.4M | −$2.8M | −$2.3M | −$2.7M | −$7.5M | −$12.0M | −$1.6M | −$3.8M | −$1.6M | −$4.4M |
| Income taxes | — | — | — | — | — | — | — | −$377,000 | — | −$4,000 | $83,000 | −$9,000 |
| Net income | −$3.4M | −$2.8M | −$3.4M | −$2.8M | −$2.3M | −$2.7M | −$7.5M | −$11.6M | −$1.6M | −$3.8M | −$1.7M | −$4.4M |
| EBITDA | −$2.4M | −$2.5M | −$3.3M | −$2.8M | −$2.3M | −$2.7M | −$7.4M | −$11.9M | −$1.2M | −$3.7M | −$4.9M | −$4.4M |
| EPS (diluted) | −$0.21 | −$0.17 | −$0.21 | −$0.19 | −$0.15 | −$0.25 | −$1.72 | −$1.75 | −$3.30 | −$664.20 | −$0.43 | −$1344.00 |
| Gross margin | — | 204.0% | 100.0% | — | — | — | −16.7% | — | — | −1.8% | 92.0% | — |
| Operating margin | — | −10,752.0% | −911.9% | — | — | — | −121,950.0% | — | — | −3,785.7% | −4,356.2% | — |
| Net margin | — | −11,000.0% | −1,054.1% | — | — | — | −124,216.7% | — | — | −3,431.2% | −1,537.5% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ALLR's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ALLR financial results
In fiscal year 2025 (ended December 31, 2025), Allarity Therapeutics reported revenue of $0.3 million. It had a net loss of $11.2 million, a net profit margin of −3,509.7%. Diluted earnings per share came to −$0.80.
See the ALLR stock overview for the latest quote and news, or the ALLR chart for price history and technical indicators.
ALLR income statement FAQ
What is Allarity Therapeutics's annual revenue?
Allarity Therapeutics reported total revenue of $0.3 million for fiscal year 2025, which ended on December 31, 2025.
Is Allarity Therapeutics profitable?
No. Allarity Therapeutics reported a net loss of $11.2 million in fiscal 2025, a net profit margin of −3,509.7%; its operating margin was −3,939.1%.
What is Allarity Therapeutics's gross margin?
Allarity Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Allarity Therapeutics kept $100 after the direct cost of its products and services.
How much does Allarity Therapeutics spend on research and development?
Allarity Therapeutics spent $6.6 million on research and development in fiscal 2025, 2,062.8% of revenue.
What are Allarity Therapeutics's earnings per share?
Allarity Therapeutics earned $-0.80 per diluted share in fiscal 2025, compared with $-670.97 a year earlier.
When will Allarity Therapeutics report its next earnings?
Allarity Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Allarity Therapeutics's fiscal year end?
Allarity Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.